Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 déc. 2025 08h01 HE | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by...
01 déc. 2025 12h00 HE | Source: Longeveron

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.
19 nov. 2025 09h15 HE | Source: Longeveron

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.